Efficacy of astragalus polysaccharides (PG2) in alleviating chemotherapy-induced fatigue in gynecologic cancer: a retrospective cohort study
Abstract Background Cancer related fatigue (CRF) is a common and debilitating side effect among gynecologic cancer patients undergoing chemotherapy. Astragalus polysaccharides (PG2), an immunomodulatory drug, has shown promise in relieving CRF. This study aimed to evaluate the effectiveness of PG2 i...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-07-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-03120-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849331859099484160 |
|---|---|
| author | Chia-Ching Chang Yi-Liang Lee Chih-Hsiang Yin Cheng-Chang Chang Yi-Hsin Lin |
| author_facet | Chia-Ching Chang Yi-Liang Lee Chih-Hsiang Yin Cheng-Chang Chang Yi-Hsin Lin |
| author_sort | Chia-Ching Chang |
| collection | DOAJ |
| description | Abstract Background Cancer related fatigue (CRF) is a common and debilitating side effect among gynecologic cancer patients undergoing chemotherapy. Astragalus polysaccharides (PG2), an immunomodulatory drug, has shown promise in relieving CRF. This study aimed to evaluate the effectiveness of PG2 in managing CRF in gynecologic cancer patients. Methods This retrospective cohort study was performed at the Department of Obstetrics & Gynecology, Tri-Service General Hospital from December 2015 to December 2022. Of 53 patients included, 40 received PG2 with chemotherapy, while 13 received chemotherapy alone. Outcomes included CRF severity and HRQL, assessed via Brief Fatigue Inventory (BFI) and Functional Assessment of Cancer Therapy-General 7 (FACT-G7), plus safety profiles. Results PG2-treated patients showed a statistically significant reduction in CRF severity, as reflected by lower BFI (p < 0.001). The PG2 group showed trends toward improved HRQL and reduced appetite loss, though not statistically significant (p > 0.05). PG2’s safety profile aligned with the control group, showing no increase in grade 3/4 toxicities. Conclusion The study concludes that PG2 shows promise as an adjunct therapy in the management of CRF among patients with gynecologic cancer receiving chemotherapy. However, the findings highlight the need for additional prospective, randomized controlled trials to rule out the risk of bias and ascertain PG2’s full therapeutic potential in oncology supportive care. |
| format | Article |
| id | doaj-art-f9fc6e682d4a4eacb55338a1e1bbfe2e |
| institution | Kabale University |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-f9fc6e682d4a4eacb55338a1e1bbfe2e2025-08-20T03:46:23ZengSpringerDiscover Oncology2730-60112025-07-0116111110.1007/s12672-025-03120-yEfficacy of astragalus polysaccharides (PG2) in alleviating chemotherapy-induced fatigue in gynecologic cancer: a retrospective cohort studyChia-Ching Chang0Yi-Liang Lee1Chih-Hsiang Yin2Cheng-Chang Chang3Yi-Hsin Lin4Department of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical CenterDepartment of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical CenterDepartment of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical CenterDepartment of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical CenterDepartment of Obstetrics and Gynecology, Tri-Service General Hospital, National Defense Medical CenterAbstract Background Cancer related fatigue (CRF) is a common and debilitating side effect among gynecologic cancer patients undergoing chemotherapy. Astragalus polysaccharides (PG2), an immunomodulatory drug, has shown promise in relieving CRF. This study aimed to evaluate the effectiveness of PG2 in managing CRF in gynecologic cancer patients. Methods This retrospective cohort study was performed at the Department of Obstetrics & Gynecology, Tri-Service General Hospital from December 2015 to December 2022. Of 53 patients included, 40 received PG2 with chemotherapy, while 13 received chemotherapy alone. Outcomes included CRF severity and HRQL, assessed via Brief Fatigue Inventory (BFI) and Functional Assessment of Cancer Therapy-General 7 (FACT-G7), plus safety profiles. Results PG2-treated patients showed a statistically significant reduction in CRF severity, as reflected by lower BFI (p < 0.001). The PG2 group showed trends toward improved HRQL and reduced appetite loss, though not statistically significant (p > 0.05). PG2’s safety profile aligned with the control group, showing no increase in grade 3/4 toxicities. Conclusion The study concludes that PG2 shows promise as an adjunct therapy in the management of CRF among patients with gynecologic cancer receiving chemotherapy. However, the findings highlight the need for additional prospective, randomized controlled trials to rule out the risk of bias and ascertain PG2’s full therapeutic potential in oncology supportive care.https://doi.org/10.1007/s12672-025-03120-yCancer-related fatigueGynecologic cancerChemotherapyAstragalus polysaccharidesPG2Quality of life |
| spellingShingle | Chia-Ching Chang Yi-Liang Lee Chih-Hsiang Yin Cheng-Chang Chang Yi-Hsin Lin Efficacy of astragalus polysaccharides (PG2) in alleviating chemotherapy-induced fatigue in gynecologic cancer: a retrospective cohort study Discover Oncology Cancer-related fatigue Gynecologic cancer Chemotherapy Astragalus polysaccharides PG2 Quality of life |
| title | Efficacy of astragalus polysaccharides (PG2) in alleviating chemotherapy-induced fatigue in gynecologic cancer: a retrospective cohort study |
| title_full | Efficacy of astragalus polysaccharides (PG2) in alleviating chemotherapy-induced fatigue in gynecologic cancer: a retrospective cohort study |
| title_fullStr | Efficacy of astragalus polysaccharides (PG2) in alleviating chemotherapy-induced fatigue in gynecologic cancer: a retrospective cohort study |
| title_full_unstemmed | Efficacy of astragalus polysaccharides (PG2) in alleviating chemotherapy-induced fatigue in gynecologic cancer: a retrospective cohort study |
| title_short | Efficacy of astragalus polysaccharides (PG2) in alleviating chemotherapy-induced fatigue in gynecologic cancer: a retrospective cohort study |
| title_sort | efficacy of astragalus polysaccharides pg2 in alleviating chemotherapy induced fatigue in gynecologic cancer a retrospective cohort study |
| topic | Cancer-related fatigue Gynecologic cancer Chemotherapy Astragalus polysaccharides PG2 Quality of life |
| url | https://doi.org/10.1007/s12672-025-03120-y |
| work_keys_str_mv | AT chiachingchang efficacyofastragaluspolysaccharidespg2inalleviatingchemotherapyinducedfatigueingynecologiccanceraretrospectivecohortstudy AT yilianglee efficacyofastragaluspolysaccharidespg2inalleviatingchemotherapyinducedfatigueingynecologiccanceraretrospectivecohortstudy AT chihhsiangyin efficacyofastragaluspolysaccharidespg2inalleviatingchemotherapyinducedfatigueingynecologiccanceraretrospectivecohortstudy AT chengchangchang efficacyofastragaluspolysaccharidespg2inalleviatingchemotherapyinducedfatigueingynecologiccanceraretrospectivecohortstudy AT yihsinlin efficacyofastragaluspolysaccharidespg2inalleviatingchemotherapyinducedfatigueingynecologiccanceraretrospectivecohortstudy |